онкология аденомакарцинома яичника

The private residence costs{stands} research ICON-3 in which 2039 patients Ic-IV with stages of a cancer яичников have taken part. In control group patients received карбоплатин in doze AUC> 5 or combination САР (500/50/50 mg / m2), in compared group - a combination цисплатина and паклитаксела (75/175 mg / m2). Treatment was carried out{was spent} each 3 weeks in volume of 6 rates. The preliminary data testify that time before progressing and general life expectancy was identical irrespective of used chemotherapy. Sick (57 %) in group карбоплатина and CAP received the majority таксаны as chemotherapy of the second line that explains rather good remote results. Подробнее...

Results of one of the most representative on number of participants (9366 patients with an operable cancer dairy железы in менопаузе) researches АТАС in which comparison of efficiency тамоксифена (20 mg / day is lead{carried out}), анастрозола (1 mg / day) and are submitted to their combination at адъювантном application within 5 years. Подробнее...